![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Acknowledgements
The study commented upon here was supported by an unrestricted research grant from Novo Nordisk to Niigata University of Pharmacy. The publication of the study and this Letter was supported by Novo Nordisk A/S (Bagsværd, Denmark) with editorial assistance from ESP Bioscience (Sandhurst, UK). All the authors declare that they do not have any relevant financial interests related to the content of the article (or this Letter). In addition, with regards to the study, the authors were wholly responsible for study design, technical measurements, analysis and scientific evaluation. All authors have read and approved the final draft of this response Letter.
Notes
* FlexPen is a registered trade name of Novo Nordisk, A/S, Bagsværd, Denmark; SoloSTAR is a registered trade name of sanofi-aventis, Paris, France
* Apidra and LANTUS are registered trade names of sanofi-aventis, Paris, France
** FlexPen is a registered trade name of Novo Nordisk, A/S, Bagsværd, Denmark. SoloSTAR is a registered trade name of sanofi-aventis, Paris, France